X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to assess the compatibility of Emergex’s immunotherapeutic candidates, including EMX-001 (dengueTcP) with the DEKA Intradermal Therapeutic Applicator.
Lead Product(s): DengueTcP
Therapeutic Area: Infections and Infectious Diseases Product Name: EMX-001
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: DEKA Research & Development
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 16, 2024
Details:
CoronaTcP (PepGNP-COVID19 Vaccine) designed to be broadly effective against disease caused by Betacoronaviruses, including SARS-CoV-1, as well as known and emerging variants of SARS-CoV-2.
Lead Product(s): PepGNP-COVID19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaTcP
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
The assets acquired include Zosano’s proprietary microneedle array patch (MAP) intradermal drug delivery system, intended for the epidermal delivery of M207 (zolmitriptan) for the treatment of migraine attacks in adults.
Lead Product(s): Zolmitriptan
Therapeutic Area: Neurology Product Name: M207
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Zosano Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 18, 2023
Details:
The agreement aims for advancing Emergex’s novel T cell-priming immune set-point candidates against designated infectious diseases, including CoronaTcP, a multi-target T cell-priming set-point product, for Betacoronaviruses and DengueTcP, a candidate against Dengue virus.
Lead Product(s): CD8+ T-cell Adaptive Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: naNO-Dengue
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Vaccine Industrial Company
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2023
Details:
Under the collaboration, Emergex and IBMP have agreed to co-fund Phase II and Phase III studies in Brazil of Emergex’s T cell-priming set-point candidates for Dengue Fever and Betacoronavirus, known respectively as DengueTcP™ (EMX-001) and CoronaTcP™.
Lead Product(s): EMX-001
Therapeutic Area: Infections and Infectious Diseases Product Name: DengueTcP
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: IBMP
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 20, 2023
Details:
DengueTcP (CD8+ T Cell Adaptive Vaccine) immune set-point product to treat dengue, is designed to elicit a specific CD8+ T cell immune response without affecting the humoral response.
Lead Product(s): CD8+ T Cell Adaptive Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DengueTcP
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: University of Lausanne Hospitals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
The ligandome library which contains viral and self MHC class I peptides has been established successfully by using the Emergex proprietary vaccine development platform, which provides a rational basis for CD8+ T cell vaccine development.
Lead Product(s): T Cell Adaptive Chikungunya Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
The MAP technology developed by Zosano is an exceptional strategic fit that complements our CD8+ T cell Adaptive Vaccine platform and intend to develop the MAP technology acquired from Zosano for delivery of vaccines.
Lead Product(s): CD8+ T-cell Adaptive Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: Zosano Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 12, 2022
Details:
The agreement initially focuses on Emergex’s Dengue vaccine candidate and also includes the shared development and commercialisation of COVID-19 and Chikungunya vaccine candidates.
Lead Product(s): CD8+ T Cell Adaptive Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Molecular Biology Institute of Parana
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 01, 2022
Details:
Emergex intends to use its previously determined repertoire of Class I peptides to generate a CD8+ T cell Adaptive Vaccine as medical countermeasure for better preparedness against naturally occurring, accidental, or deliberate exposures to the bacterium that causes tularemia.
Lead Product(s): Tularemia Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
